Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting
Harvard Bioscience (HBIO) will showcase its latest product innovations at the Society of Toxicology conference in Orlando from March 17-20, 2025. The company is presenting three major solutions:
1. The expanded SoHo™ Implantable Real-Time Telemetry Platform, which includes new biopotential monitoring devices for neurotoxicity and cardiovascular toxicology studies. The platform integrates with Ponemah data management system to automate data collection and analysis.
2. The VivaMARS™ Activity Monitoring System, a GLP-compliant platform for real-time behavioral analysis, aimed at CROs and pharmaceutical companies for neuropharmacology applications.
3. The Mesh MEA™ Organoid Platform, designed for real-time electrophysiological readings from living organoids, supporting research, safety pharmacology, and toxicology studies. The NIH has recently adopted this system for advanced neuro organoid research.
Harvard Bioscience (HBIO) presenterà le sue ultime innovazioni di prodotto al congresso della Society of Toxicology a Orlando dal 17 al 20 marzo 2025. L'azienda presenterà tre soluzioni principali:
1. La piattaforma espansa SoHo™ Implantable Real-Time Telemetry Platform, che include nuovi dispositivi di monitoraggio biopotenziale per studi di neurotossicità e tossicologia cardiovascolare. La piattaforma si integra con il sistema di gestione dei dati Ponemah per automatizzare la raccolta e l'analisi dei dati.
2. Il VivaMARS™ Activity Monitoring System, una piattaforma conforme GLP per l'analisi comportamentale in tempo reale, destinata a CRO e aziende farmaceutiche per applicazioni di neurofarmacologia.
3. La Mesh MEA™ Organoid Platform, progettata per letture elettrofisiologiche in tempo reale da organoidi vivi, supportando la ricerca, la farmacologia di sicurezza e studi di tossicologia. Il NIH ha recentemente adottato questo sistema per la ricerca avanzata sugli organoidi neurali.
Harvard Bioscience (HBIO) presentará sus últimas innovaciones de productos en la conferencia de la Society of Toxicology en Orlando del 17 al 20 de marzo de 2025. La empresa presentará tres soluciones principales:
1. La plataforma ampliada SoHo™ Implantable Real-Time Telemetry Platform, que incluye nuevos dispositivos de monitoreo de biopotenciales para estudios de neurotoxicidad y toxicología cardiovascular. La plataforma se integra con el sistema de gestión de datos Ponemah para automatizar la recopilación y el análisis de datos.
2. El VivaMARS™ Activity Monitoring System, una plataforma conforme a GLP para el análisis del comportamiento en tiempo real, dirigida a CRO y empresas farmacéuticas para aplicaciones de neurofarmacología.
3. La Mesh MEA™ Organoid Platform, diseñada para lecturas electrofisiológicas en tiempo real de organoides vivos, apoyando la investigación, la farmacología de seguridad y estudios de toxicología. El NIH ha adoptado recientemente este sistema para la investigación avanzada de organoides neuronales.
하버드 바이오사이언스 (HBIO)는 2025년 3월 17일부터 20일까지 올랜도에서 열리는 독성학회에서 최신 제품 혁신을 선보일 예정입니다. 회사는 세 가지 주요 솔루션을 발표합니다:
1. 새로운 생체 전위 모니터링 장치를 포함한 확장된 SoHo™ Implantable Real-Time Telemetry Platform으로, 신경 독성 및 심혈관 독성 연구에 사용됩니다. 이 플랫폼은 데이터 수집 및 분석을 자동화하기 위해 Ponemah 데이터 관리 시스템과 통합됩니다.
2. GLP 준수 플랫폼인 VivaMARS™ Activity Monitoring System으로, 신경 약리학 응용을 위해 CRO 및 제약 회사를 대상으로 실시간 행동 분석을 제공합니다.
3. 살아있는 오르가노이드에서 실시간 전기생리학적 측정을 위한 Mesh MEA™ Organoid Platform으로, 연구, 안전성 약리학 및 독성학 연구를 지원합니다. NIH는 최근 이 시스템을 고급 신경 오르가노이드 연구에 채택했습니다.
Harvard Bioscience (HBIO) présentera ses dernières innovations produits lors de la conférence de la Society of Toxicology à Orlando du 17 au 20 mars 2025. L'entreprise présentera trois solutions principales :
1. La plateforme élargie SoHo™ Implantable Real-Time Telemetry Platform, qui comprend de nouveaux dispositifs de surveillance des biopotentiels pour les études de neurotoxicité et de toxicologie cardiovasculaire. La plateforme s'intègre au système de gestion des données Ponemah pour automatiser la collecte et l'analyse des données.
2. Le VivaMARS™ Activity Monitoring System, une plateforme conforme aux GLP pour l'analyse comportementale en temps réel, destinée aux CRO et aux entreprises pharmaceutiques pour des applications en neuropharmacologie.
3. La Mesh MEA™ Organoid Platform, conçue pour des lectures électrophysiologiques en temps réel à partir d'organoïdes vivants, soutenant la recherche, la pharmacologie de sécurité et les études de toxicologie. Les NIH ont récemment adopté ce système pour la recherche avancée sur les organoïdes neuronaux.
Harvard Bioscience (HBIO) wird ihre neuesten Produktinnovationen auf der Konferenz der Society of Toxicology in Orlando vom 17. bis 20. März 2025 vorstellen. Das Unternehmen präsentiert drei Hauptlösungen:
1. Die erweiterte SoHo™ Implantable Real-Time Telemetry Platform, die neue biopotenzielle Überwachungsgeräte für Studien zur Neurotoxizität und kardiovaskulären Toxikologie umfasst. Die Plattform integriert sich mit dem Ponemah-Datenmanagementsystem, um die Datensammlung und -analyse zu automatisieren.
2. Das VivaMARS™ Activity Monitoring System, eine GLP-konforme Plattform für die Verhaltensanalyse in Echtzeit, die sich an CROs und Pharmaunternehmen für Anwendungen in der Neuropharmakologie richtet.
3. Die Mesh MEA™ Organoid Platform, die für Echtzeit-elektrophysiologische Messungen von lebenden Organoiden konzipiert ist und die Forschung, Sicherheitspharmakologie und toxikologische Studien unterstützt. Das NIH hat dieses System kürzlich für fortgeschrittene neuro-organoid Forschung übernommen.
- NIH's adoption of Mesh MEA technology for neuro organoid research
- Integration capabilities of SoHo platform with GLP-compliant Ponemah system
- Platform solutions aimed at reducing operating costs and test cycle times
- Growing adoption of Mesh MEA technology for longitudinal organoid applications
- None.
Insights
Harvard Bioscience's latest product showcase reveals a strategic focus on high-growth segments within the $47 billion preclinical research market. The company's enhanced product portfolio addresses three critical industry pain points: operational efficiency, data quality, and cost reduction.
The expanded SoHo telemetry platform represents a significant advancement in preclinical research efficiency. By enabling simultaneous monitoring of multiple animal models and incorporating AI-based analysis capabilities, this system could reduce study durations by 30-40% while improving data quality. This efficiency gain directly translates to increased testing capacity for CROs and pharmaceutical companies, potentially generating higher recurring revenue through increased consumable usage.
The VivaMARS system's GLP-compliance and integration with Ponemah software creates a compelling value proposition for neuropharmacology applications. This is particularly timely given the industry's increasing focus on CNS drug development, where precise behavioral analysis is crucial. The collaboration with a leading CRO for early adoption suggests strong market validation and could accelerate broader market acceptance.
The Mesh MEA organoid platform's adoption by the NIH is especially noteworthy. Organoid research is experiencing rapid growth, with the global organoid market projected to reach $3.1 billion by 2027. The platform's ability to provide real-time electrophysiological readings from within living organoids addresses a significant technical challenge in the field. This positions Harvard Bioscience to capture a meaningful share of this expanding market segment.
These innovations collectively strengthen Harvard Bioscience's competitive moat through:
- Enhanced software integration and data management capabilities
- Improved operational efficiency for customers
- Expanded applications in high-growth research areas
The company's focus on reducing customer operating costs while enabling higher testing throughput could drive stronger customer retention and recurring revenue growth. The AI-based analysis capabilities also align with the industry's movement toward automated, high-throughput screening methods, potentially opening new revenue streams in data analytics services.
Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity
HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 17-20, 2025, in Orlando. Building upon its comprehensive product portfolio, these latest developments open promising new avenues for progressing preclinical research and organoid-based therapeutic development.
Expansion of SoHo™ Implantable Real-Time Telemetry Platform
The SoHo telemetry solution enables researchers to collect, manage, analyze and report findings from multiple concurrent small animal models in both shared housing and extended range environments. The Company will unveil its newly launched SoHo biopotential monitoring devices used in many study types including neurotoxicity and cardiovascular toxicology studies.
The SoHo telemetry platform integrates with the Company’s GLP-compliant Ponemah data management platform which automates data collection, analysis, and reporting, to reduce manual effort and improve consistency in results. The system supports the customer’s business needs by reducing operating costs and test cycle times, enabling increased testing throughput and possibilities for emerging AI-based analysis of preclinical datasets. For more information visit the DSI website at https://www.datasci.com/products/implantable-telemetry/soho-telemetry-system/.
Company to Present on VivaMARS™ Activity Monitoring System
Powered by Ponemah, the VivaMARS system delivers a comprehensive, GLP-compliant platform for precise, real-time behavioral analysis. This integrated solution addresses the demands of CROs and pharmaceutical companies to reduce cycle times and increase revenue streams, especially with neuropharmacology and neurotoxicology applications.
On March 20th the Company will be presenting a poster prepared in cooperation with a leading CRO, the first adopter of the VivaMARS technology. To learn more about the VivaMARS system, visit the DSI website at https://www.datasci.com/products/behavior/vivamars-mobile-activity-rack-system/.
Multi Channel Systems Mesh MEA™ Organoid Platform
The Company will also be highlighting its innovative Mesh Microelectrode Array (MEA) platform, specifically engineered for organoid applications. Building upon its established expertise in in vitro MEA technology, this groundbreaking Mesh MEA™ system enables scientists to obtain detailed, real-time electrophysiological readings from within living organoids. This advanced platform has been purposefully developed to support the growing demand of organoid usage across research and discovery, as well as safety pharmacology and toxicology studies. Learn more about Mesh MEA and organoid research capabilities at https://www.harvardbioscience.com/applications/organoid-research/.
Solutions for New Therapy Development
Jim Green, Harvard Bioscience Chairman and CEO, said, "We are excited to showcase our latest technological breakthroughs at this year's SOT meeting. These innovations advance the science while lowering costs and reducing time to market for biopharma’s new generations of drugs and therapies.” Green continued, “We are pleased to see the rapidly growing adoption of the Mesh MEA technology for longitudinal organoid applications, including the NIH’s decision this month to adopt and initiate advanced neuro organoid research utilizing our system.”
Booth at Society of Toxicology
The Company will be exhibiting a range of solutions at Society of Toxicology booth #1411, at the Orange County Convention Center (Orlando, FL). Representatives will be present during exhibit hours from Monday, March 17, 2025, through Wednesday, March 19, 2025.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at https://www.harvardbioscience.com.
Inquiries:
Customers
Investors and Media Contact:
Three Part Advisors
Sandy Martin
HBIO@threepa.com
(214) 616-2207
FAQ
What new products will HBIO showcase at the 2025 Society of Toxicology conference?
How does HBIO's SoHo telemetry platform improve research efficiency?
What is the significance of NIH adopting HBIO's Mesh MEA technology in 2025?
What are the main applications of HBIO's VivaMARS system?
When and where will HBIO exhibit at the 2025 Society of Toxicology conference?
